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Lidocaine Prophylaxis in Acute Myocardial Infarction

James E. Tisdale, PharmD*

The prophylactic adminisiration of lidocaine for the prevention of primary ventricular fibrillatitm
(VF) foltowing suspected acute myocardial infarction (Ml) is controversial. The incidence of primaiy
VF foUowing acute Ml ranges from 1.8% to 10.5%. "Warning arrhythmias" have not been shown lo
be reliable predictors of VF. In-hospital prophylactic administration (rf lidocaine has heen shown
to decrease the incidence of primary VF. whereas prehospital administration has not. However,
prophylactic adminislralion of lidocaine has not heen shown to have a beneficial effect on mortatity
and may in fact increase mortality. The incidence of tidocaine-induced adverse effects during
prophylaxis ranges from 4% to 85%, wdh an average of approximately 35%. In view (rf the low
incidence of primaiy VF following acute Ml, the high incidence of tidocaine-induced adverse effects,
and the lack of evidence of beneficial effect on mortatity. prophylactic lidocaine administration to all
patients wilh suspected Ml is not recommended. The American Hearl Association and American
College (rf Cardiology recommend prophylactic lidocaine adminislralion in patients with acule
myocardial ischemia or Ml who have ventricular premature heats that occur frequently (> 6 per
minute), are closely coupled (R on T). multiform in configuration, or occur in short hursts of three or
more in succession. (Henry Ford Hosp MedJ 1991:39:2l7-25)

T

he prophylactic administration of lidocaine to patients with
suspected acute myocardial infarction (MI) for the prevention of primary ventricular fibrillation (VF) has been a controversial issue for more than 20 years. In the late 1960s it was suggested that suppression of so-called "waming arrhythmias"
such as ventricular premature beats (VPBs), couplets, multiform
complexes, and nonsustained ventricular tachycardia may resull
in complete prevention of primary VF in patients in coronary
care units (1). It soon became evident, however, that these
"waming arrhythmias" were not reliable predictors of VF (2-4),
and the routine administration of lidocaine to all patients with
suspected acute M I was advocated (5,6). Since then, prophylactic administration of lidocaine has become standard therapy for
patients with suspected M I in many centers in the United States
(7,8). However, many clinicians and investigators have discouraged routine lidocaine prophylaxis based on the low frequency
of primary VF following acute M I , the occurrence of lidocaine
toxicity during routine lidocaine prophylaxis, and the lack of evidence of beneficial effect on mortality (9,10). This article reviews the incidence of primary VF following acute M I , the reliability of "waming arrhythmias" as predictors of VF, published
studies evaluating the efficacy of lidocaine prophylaxis in patients with suspecled M I , and the incidence of lidocaine toxicity
during primary VF prophylaxis. The guidelines for lidocaine
prophylaxis published by the American College of Cardiology
and the American Heart Association also are reviewed.

Primary VF Complicating Acute MI
The incidence of primary VF, defined as one or more episodes of VF lhat occur in the absence of congestive heart failure

Henry Ford Hosp Med J—Vol 39, Nos 3 & 4, 1991

or shock (11), in patients with confirmed acute M l ranges from
1.8% to 10.5% (Table 1) (3,4,9,12-28). The incidence of primary VF following M I is inversely proportional to the duration
of time from the onset of symptoms to hospital admission (3,
13,23). In one study of patients with acute M I who experienced
primary VF, 71% did so within 4 hours, 83% within 8 hours, and
96% within 24 hours of the onset of symptoms (13). In a study
reporting the incidence of primary VF in untreated patients with
acute M I and in tho.se treated prophylactically with lidocaine,
28% of VF episodes occurred within 2 hours, 61% within 4
hours, and 78% wilhin 6 hours of the onset of symptoms (3). A l l
patients who experienced primary VF did so within 24 hours of
the onset of symptoms (3). In another trial, 41% of M I patients
who developed VF did so within 4 hours, 65% within 8 hours,
and 94% within 24 hours ofthe onset of symptoms (23).
A number of factors have been associated with an increased
risk of VF following M I . In an analysis of factors that predicted
cardiac arrest in 905 patients admitted with the diagnosis of
acute M I , history of congestive heart failure and previous M l
were identified as significant predictors (24). The incidence of
primary VF following M l may be higher in patients with diabetes mellitus (29). Primary VF post-MI appears to occur less
commonly in patients who are greater than 65 or 70 years of age
than in younger individuals (2,3,13,22,23,27). The influence of
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Table 1
Incidence of Primary Ventricular Fibrillation
Following Acute Myocardial Infarction

Reference

n

Goble etal, 1966(12)
Lawrieetal, 1968(13)

67
198

Church & Biem,
1969(14)
Benneu etal, 1970(15)

183
125

Mogenson, 1970(16)

242

Baker etal, 1971 (17)

23

Church &Biern, 1972(18)
Darby et al. 1972(19)

44
100

Bleifeld etal, 1973 (20)

4S

O'Brien etal, 1973(21)
Lie etal, 1974(3)

255

Lie etal, 1974(22)

105

Lie etal, 1975 (4)

262

El-Sherifetal, 1976(23)

450

Conley et al. 1977 (24)
Lie etal, 1977 (25)
Koster & Dunning, 1985 (26)
Dubois et al. 1986(28)
Volpietal, 1987(27)

Time From Onset of
Symptoms to Admission

14(1

527
76
929
1,265
11.712

< 24 hrs
0-4 hrs (58%)
> 4 hrs (42%)
0-4 hrs (48%)
< 12 hrs (73%)
0-3 hrs (34%)
4-12 hrs (38%)
13-48 hrs (28%)
0-3 hrs (40%)
4-6 hrs (22%)
> 6 hrs (38%)
< 4 hrs (35%)
< 12 hrs (65%)
0-4 hrs (68%)
0-3 hrs (46%)
4-12 hrs (35%)
13-48 hrs (19%)
1-5 hrs (25%)
6-24 hrs (35%)
25-48 hrs (217c)
Not reported
< 24 hrs
(mean = 4 hours)
< 2 hrs (49%)
2-4 hrs (34%)
4-6 hrs (17%)
< 6 hrs
(< 2.5 hrs, 50%)
< 24 hrs
(mean = 4 hrs)
Not reported
<6hrs
2-3 hrs (median)
8.4 hrs (mean)
< 12 hrs

Numberof Patients
with VF (%)
5 (7,5)
20(10,1)
19(10,4)
7(5,6)
8(3,3)
2(8,7)
3(6,8)
3(3,0)
2(4,2)
5 (3,4)
11 (4,3)
11 (10,5)
20 (7,6)
20 (4,4)
45 (8,5)
2(2,6)
17(1,8)
96 (7,6)
332 (2,8)

VF = ventricular fibrillation.

infarct site on the incidence of primary VF is not well studied.
One study reported a trend towards an increased incidence of
primary VF in patients experiencing anterior wall infarctions
(23). However, other investigators have been unable to demonstrate an infiuence of infarct site on the incidence of primary VF
(24,30). The effect of infarct size on the incidence of primary VF
also has not been well studied. Lie and associates (4) found that
peak SGOT concentrations were higher in patients who developed primary VF following Ml than in those who did not, but
the statistical significance of this difference was not reported.
Other factors such as sex and heart rate have not been shown to
be significant risk factors for the development of primary VF
fotiowing acute MI (4,23,31).
The incidence of recurrence of VF in patients who experience
primary VF following acute MI ranges from 8% to 67% (3,
13,23). Recurrences of primary VF typically occur within 8
hours of the initial episode (3).
Primary VF following acute Ml appears to be associated with
increased in-hospital mortality. In-hospital mortality for such
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patients ranges from 0% to 50% (2,3,12,13,16,22,23,28,32-34).
Pooled results from 13 studies indicate that the mean incidence
of mortality associated with postinfarction VF is 19% (35). In
comparison, in-hospital mortality for patients with uncomplicated MI who do not experience primary VF ranges from 3% to
13% (mean 8%) (12,16,28,32-35). This difference was not evaluated statistically (35). However, most studies indicate that the
long-term prognosis of patients who survive primary VF postinfarction is not significantly different from that of MI patients
who do not have an episode of primary VF (24,35-38).

Reliability of "Warning Arrhythmias" for the
Prediction of Primary VF Following MI
In the 1960s, several investigators promoted the use of specific "premonitory" or "waming arrhythmias" for the prediction
of the occurrence of primary VF postinfarction (1,30,39). Lown
et al (1) observed no episodes of primary VF in 130 consecutive
patients admitted wilh acute MI and attributed this to the routine
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administration of lidocaine to all patients exhibiting the R-on-T
phenomenon, two or more consecutive VPBs, multiform VPBs,
or greater than five VPBs per minute. Another group of investigators reported that six of 32 Ml patients in whom VPBs occurred frequently (one VPB to every 2 to 10 beats) developed
VF, compared to one of 35 Ml patients who had less frequent
VPBs (31). Meltzer and Kitchell (39) suggested that the occurrence of greater than six VPBs per minute, ventricular tachycardia, third-degree heart block, or a previous episode of VF should
be considered predictors of primary VF. As a result of these
findings and recommendations, based on data obtained in uncontrolled studies, routine administration of lidocaine to MI patients with "waming arrhythmias," or specific ventricular ectopic acfivity (VEA), became common.
Since the publication of those early papers, however, the utility of specific VEA for the prediction of primary VF has been
challenged. While some investigators have found specific VEA
to occur in 71 % to 81 % of MI patients who experience primary
VF (2,40,41), the majority of studies indicate that the incidence
of specific VEA in patients with primary VF postinfarction is
subslantially lower. Lawrie and associates (13) detected specific
VEA in only two (17%) of 12 MI patients who experienced primary VF. Church and Biem (14) observed specific VEA in six
(46%) of 13 post-MI patients experiencing primary VF. Other
studies have reported the occurrence of specific VEA in only
43% to 60% of MI patients prior to the onset of primary VF
(3,4,9,22,23,42). Furthermore, specific VEA has been detected
in 29% to 59% of MI pafients who do not develop primary VF
(4,22,23,30). Because VEA occurs with similar frequency in MI
patients who develop primary VF and in those who do not, the
occurrence of VEA cannot be considered a reliable predictor of
primary VF following MI (35,43).

Moreover, in many of these studies relatively low lidocaine bolus and/or maintenance doses were administered (15,16,18-20,
44,46), and some trials evaluated single intramuscular doses of
lidocaine (25,47,48). Additionally, the majority of investigators
did not determine plasma lidocaine concentrations in study patients (15,17-20,25,44-46,49), and plasma lidocaine concentrations were subtherapeutic or barely therapeutic (therapeutic
range: 2 to 6 |ig/mL [50]) in some studies in which they were determined (47,48). Therefore, the lack of efficacy of prophylactic
lidocaine administration in many studies may have been due to
the administration of inadequate doses of the drug. Deficiencies
of study design, therefore, leave the results of many of these
studies open to some question.
Perhaps the most well-designed study for the evaluation of
the efficacy of prophylactic lidocaine administration in acute Ml
was performed by Lie and associates (22) (Table 2). In this double-blind trial, 212 patients with confirmed MI who were admitted within 6 hours of the onset of chest pain were randomized
to receive intravenous lidocaine (100 mg load followed by a
continuous infusion of 3 mg/minute for 48 hours) or placebo.
Plasma lidocaine concentrations in patients randomized to the
trealment group were within the therapeutic range (mean 3.5 +
0.9 |J,g/mL, range 1.5 to 6.4 pg/mL). The incidence of primary
VF was significantly lower in the lidocaine group than in the
placebo group. Based on the results of this trial, it has been concluded that prophylactic lidocaine administration decreases the
incidence of primary VF following acute Ml (43).

In a retrospective data review, Wyman and Hammersmith (5)
attributed a substantial reduction in the incidence of primary VF
following acute Ml to the prophylactic administration of lidocaine. In this study, 1,165 patients admitted with confirmed MI
(58% were admitted within 4 hours of the onset of chest pain)
over a seven-year period were administered drug therapy for the
prophylaxis of primary VF according to different criteria. Of
Efficacy of In-hospital Administration
139 patients for whom prophylaxis was limited to orally adminof Lidocaine for the Prevention of
istered procainamide or quinidine upon detection of VEA, nine
Primary VF Following Acute MI
(6.5%) experienced primary VF. Of 1,026 patients who received
prophylactic lidocaine, three (0.3%) had an episode of primary
Randomized studies investigating the efficacy of in-hospital
VF. Although this was a retrospective, uncontrolled study, these
administration of lidocaine for the prophylaxis of primary VF
data
also lend support to evidence that prophylactic lidocaine
following MI are presented in Table 2.
administration
reduces the incidence of primary VF following
The majority of studies found no significant difference in the
acute
MI.
incidence of primary VF in patients randomized to receive lidocaine compared to those randomized to receive placebo (15Two meta-analyses have been performed to determine the ef18,21,25,44-49) or no treatment (19,20). However, interpretaficacy of lidocaine prophylaxis for the prevention of primary VF
tion of the results of some of these trials is impaired by deficienin patients following acute MI. DeSilva and colleagues (51)
cies in study design. Small sample sizes were evaluated in a
pooled the results of six randomized studies (15,16,18,20-22)
number of these studies (16-18,20,44,46). Some of these trials
according to the following criteria: presence of acute MI, lidowere not blinded (15,16,19,20,45) or placebo-controlled (15,19,
caine loading dose of at least 50 mg intravenously, and lidocaine
20). Many of these studies included patients who had chest pain
maintenance infusion of not less than I mg/minute for at least 24
up to 48 (15,16,19,20) to 72 hours (46) prior to hospital admishours. The results of the pooled data demonstrated that primary
sion. In one study, the mean duration of chest pain prior to adVF occurred in 16 (3.1%) of 517 patients who received prophymission was 8 to 9 hours (45). Other studies neglected to report
lactic lidocaine, compared with 29 (5.7%) of 505 patients who
or reported incompletely the duration of chest pain in patients
received placebo or no treatment (relative risk = 0.53,95% conincluded in the study (17,18,21,44,47). Since the majority of Ml
fidence interval 0.28 to 0.98). These results indicate that propatients who experience primary VF do so within 6 hours of the
phylactic lidocaine administration significantly reduces the inon.set of chest pain (3,13,23), many of these trials included pacidence of primary VF following MI. A more recent meta-analytients who were well beyond the period of risk for primary VF. sis (52) pooled the results of 14 randomized, controlled studies
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(15,17,19,21,22,26,44-49,53,54), one of which was a prehospital study (26) (Table 3). One of the studies included in this metaanalysis makes no mention of whether the incidence of VF was
evaluated (54), and therefore this trial is not included in Table 2.
The pooled results of these studies also indicate that the incidence of primary VF postinfarction was significantly reduced in
patients who received prophylactic lidocaine compared to patients who received placebo. In this analysis, the odds of primary VF were reduced by about one-third in patients allocated
lidocaine therapy.
In summary, interpretation of results of many trials in which
the efficacy of prophylactic lidocaine for the prevention of primary VF following MI has been investigated is hampered by inadequacies of study design. However, based on the results of Lie

et al's (22) well-designed study and the results of the two metaanalyses of pooled data (51,52), it can be concluded that in-hospital prophylactic lidocaine administration reduces the incidence of primary VF following acute MI.

Efficacy of Prehospital Administration
of Lidocaine for the Prevention of
Primary VF Following Acute MI
Randomized studies investigating the efficacy of prehospital
administration of lidocaine for the prevention of primary VF
following acute Ml are outiined in Table 3.
In each of these trials, no significant difference in the incidence of primary VF was demonstrated in patients receiving

Table 2
Randomized Studies of In-Hospital Administration of Lidocaine for the Prevention
of Primary Ventricular Fibrillation Following Acute Myocardial Infarcfion*

Reference

n

Duration
of
Symptomst

Kostuk et al
(44)
Bennett et al
(15)§ll
Mogensen
(16)§1|
Baker et al
(17)
Pitt et al
(45)§
Chopra et al
(46)
Church & Biem
(18)**
Darby et al
(19)§ll
Bleifeld et al
(20)§II1|
O'Brien et al
(21)

65

NR

—

1

48

NR

374

< 48 hrs

6(1

0,5-1

48

NR

79

< 48 hrs

75

2

24

44

NR(14pts
> 12 hrs)
Mean 7,8 to
8,5 hrs
< 72 hrs

50-200

1,5-3,5

48

2,6 pg/mL
(n=15)
NR

75-100

2,5

48

NR

50-150

1-2

26

NR

222
82
86

L
Bolus
(mg)

L Infusion
Rate
(mg/min)

Duration
of Infusion
(hrs)

Mean
Plasma L
Conc,

50-75

2

48

NK

203

NR (57 pts
< 4 hrs)
< 48 hrs

200 (IM)

2

4K

NR

sy

< 48 hrs

100

1,5-3

5 days

NR

300

NR

75

2.5

4X

4,0 ng/mL
(24 hrs)
5,5 pg/mL
(48 hrs)
3,5 pg/mL
(6 hrs)
0,96-1,79
Hg/mL
(1 hr)

Lie et al
(22)
Sandler et al
(47)

212

< 6 hrs

100

3

4S

ISl

NR

—

4

Lie et al
(25)
Lie et al
(48)
Wyse et al
(49)

LSJ

<6hrs

200 (IM)
(n = 89)
300 (IM)
(n = 92)
300 (IM)

—

1

NR

300

< 6 hrs

300 (IM)

—

1

190

< 6 hrs

100 (x2)

3

24

2,1 ± 1,1
pg/mL
NR

Incidence
of
VF(%)

Incidence
of
Mortality (%)t

0/34 (0) L
0/31 (0)P
16/249 (6,4) L
7/125 (5,6) No Tx
0/42 (0) L
1/37(2,7)P
0/21 ( 0 ) L
2/23 (8,7)P
1/108 (0,9) L
0/114(0)P
1/39 (2,6) L
0/43 (0) P
4/42 (9,5 ) L
3/44(6,8) P
4/103 (3,9) L
3/100 (3) No Tx
0/41 ( 0 ) L
2/48 (4,2) No Tx
7/154 (4,5) L
5/146 (3,4) P

NR
25/249 (10) L
8/125 (6,4) No Tx
5/44#(lI,4)L
4/44#(9,l)P
3/21 (14.3) L
2/23 (8,7) P
6/108 (5,6) L
4/114 (3,5) P
7/39 (17.9) L
4/43 (9,3) P
NR
7/103 (6,8) L
5/100 (5) No Tx
2/41 (4,9) L
4/48 (8,3) No Tx
11/154 ( 7 , l ) L
4/146 (2,7) P

0/107(0) L t t
11/105 (10,5) P
0/91 ( 0 ) L
0/90 (0) P

8/107 (7,5) L
10/105 (9,5) P
NR

4/78 (5,1 ) L
2/76 (2,6) P
6/147 (4,1 ) L
4/153 (2,6) P
0/100 (0) L
1/90(1,1)P

0/78 (0) L
0/76 (0) P
5/147 (3,4) L
6/153 (3,9) P
7/100 ( 7 ) L
4/90 (4,4) P

L = lidocaine, Conc. = concentration, VF = ventricular fibrillation. P = placebo. NR = nol reported. No Tx = no treatment. IM = intramuscular, pts = patients.
•Studies were double-blind and placebo-controlled except where indicated. Administration of lidocaine was intravenous excepl where indicated. All patients reported in this table had
confirmed myocardial infarction.
iPrior to hospital admission.
^During treatment period.
§Not blinded.
IINot placebo-controlled.
^Treatment assigned by birthdate.
#Nine patients included in mortality analysis were not included in VF analysis.
**Single-blind.
t t P < 0.002.
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lidocaine compared to those receiving placebo (53,55,56) or no
treatment (26,57,58). Deficiencies in the design of these studies
warrant consideration. Some of these studies were not blinded
or placebo-controlled (26,57,58). In most of these trials, plasma
lidocaine concentrations were not determined, and therefore it is
unclear whether adequate plasma concentrations were achieved
(53,55-58). In a number of these studies, the incidence of primary VF in treatment and control groups was calculated based
on all patients with suspected MI, rather than only those with
confirmed MI (26,55,57), and therefore many patients included
for analysis were likely at very low risk for primary VF. Additional deficiencies include failure to report the duration of chest
pain prior to randomization (26,57,58) and short follow-up periods (26,53). Inadequacies in study design may account for the
reported lack of efficacy of prehospital lidocaine administrafion
for the prevention of primary VF following acute MI. Nevertheless, currentiy existing data do not support the prehospital prophylactic administration of intramuscular or intravenous loading doses of lidocaine in patients with suspected acute Ml.

Effect of Prophylactic Lidocaine Administration
on Mortality Following Acute MI
The infiuence of in-hospital prophylactic administration of
lidocaine on mortality following MI in randomized studies is
presented in Table 2.
In-hospital prophylactic lidocaine administration did not significantiy influence mortality in any study, including Lie et al's
(22) trial in which lidocaine administration resulted in a significantly lower incidence of primary VF than administration of
placebo.

The influence of prehospital prophylactic lidocaine administration on mortality following Ml in randomized studies is presented in Table 3.
In the majority of studies, prehospital administration of lidocaine did not significantly infiuence mortality. Valentine and
colleagues (55) reported that the prehospital adminisiration of
lidocaine (300 mg intramuscularly) significantiy reduced early
mortality (2 deaths out of 156 patients in the lidocaine group
versus 6 deaths out of 113 patients in the placebo group, P <
0.05). However, the authors indicate that although this was intended to be a randomized trial, nonrandom allocation of treatment may have occurred, raising the possibility of bias. In addition, early mortality was defined as that which occurred within
only 2 hours of the injecfion of drug or placebo. The incidence of
late mortality (defined as that which occurred from 2 hours to 30
days following injection) in the two groups was not significantly different.
The influence of prophylactic lidocaine administration on
early mortality following Ml was evaluated in the meta-analysis
performed by MacMahon and associates (52). The pooled incidence of mortality occurring during treatment/follow-up periods of 1 to 48 hours in the 14 studies reviewed was 82 deaths
(1.9%) out of 4,616 patients receiving prophylactic lidocaine
and 55 deaths (1.2%) out of 4,539 patients receiving placebo or
no treatment. These data indicate that the incidence of early
mortality was approximately one-third higher in the lidocaine
group than in the control group, although this difference did not
reach statistical significance (odds ratio = 1.38, 95% confidence
interval = 0.98 to 1.95). The influence of prophylactic lidocaine
administration on late mortality (death occurring after the treatment/follow-up periods) in eight studies was also examined.

Table 3
Randomized Studies of Prehospital Administration of Lidocaine for the Prevention of
Primary Ventricular Fibrillation Following Acute Myocardial Infarction*

Reference
Valentine et al
(55)1
Wennerblom et al
(56)
Dunn et al
(53)
Koster & Dunning
(26)#**
Hargarten et al
(57)#**
Hargarten et al
(58)#**

n

Percent
Confirmed
MI

L
Bolus

L
Infusion

269

NR

300 mg IM

—

NR

2 hrs

150

36

300 mg IM

—

NR

3 hrs

402

,^l

—

6,024

32

300 mg IM
100 mg IV
400 mg IM

446

29

1.427

31

0,75-1,5
mg/kg IV
0,75-1,5
mg/kg IV

—
1-2
mg/min
1-2
mg/min

Mean
Plasma
L Conc,

3,57-4,50
pg/mL
3 pg/mL
(n = 369)
NR
NR

Duration
of
Follow-up

1 hr
1 hr
POH
POH

Incidence
ofVF

(%)
1/156 (0,6) L
2/113(1,8) P
0/2811 (0) L
0/2611 (0) P
0/10811 (0)L
.3/9611 (3.1 )P
8/2987 (0,3) L
17/3037 (0,6) No Tx
3/222 (1,4) L
3/224 (1,3) No Tx
4/23611 (1,7) L
3/20011 (1,5) No Tx

Incidence
of Mortality t

(%)
2/156 (1,3) L§ll
6/113 (5,3)P
5/281 (17,9)L
5/2611 (19,2) P
5/207 (2,4) L
5/195 (2,6) P
19/2987 (0,6) L
21/.3037 (0,7) No Tx
18/222 (8,1) L
15/224 (6,7) No Tx
2/23611 (0.8) L
2/20011 (1,0) No Tx

MI = myocardial infarction. L = lidocaine. Conc. = concentration. VF = ventricular fibrillation. NR = not reported, IM - intramuscular. P = placebo. IV = intravenous. No Tx = no treatmenl, POH = period of hospitalization.
^Studies were double-blind and placebo-controlled except where indicated,
tin-hospital.
^Treatment was intended to be randomized, but aulhors indicate that nonrandom allocation may have occurred.
§P < 0.03. early mortalily (within 2 hours of injection).
IILate mortality (2-30 hours following injection) not significanlly differenl.
^Patients with confirmed myocardial infarction only.
#Noi blinded.
**Not placebo*controlled.
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The incidence of late mortality in the treatment group and placebo group was not significantly different (P > 0.3).
One published meta-analysis evaluated solely the effect of
prophylactic lidocaine administration on mortality following
acute MI (59). In this analysis, studies were included for evaluation based on the following criteria: randomized, controlled trials investigating the use of prophylactic lidocaine in patients
with proven or suspected Ml; patient enrollment within 72 hours
of symptoms; and administration of lidocaine bolus > 50 mg followed by continuous infusion of > 1.0 mg/min for at least 24
hours or bolus of at least 300 mg without subsequent infusion.
Eight hospital-phase (15,16,19-22,45,46) and six prehospitalphase (26,48,53,55-57) studies were included for evaluation.
One of the "prehospital-phase" trials analyzed was actually a
hospital-phase study (48). In the hospital-phase trials, the risk of
treatment-period mortality was significantly higher in the lidocaine group compared to the placebo group. Meta-analysis of
the risk oftotal in-hospital mortality in the hospital-phase studies revealed no statistically significant treatment effect. Analysis of the "prehospital-phase" studies demonstrated no statistically significant mortality effects related to the prophylactic administration of lidocaine.
In summary, the administration of prophylacfic lidocaine following acute MI has not been shown to have a beneficial effect
on mortality. In fact, available evidence indicates that the inhospital administration of prophylactic lidocaine following MI
may be associated with an increased risk of mortality during the
period of treatment.

Adverse Effects Associated with Prophylactic
Lidocaine Administration
Lidocaine administration may be associated with adverse effects involving primarily the central nervous system (CNS) and
the cardiovascular system. Adverse CNS effects of lidocaine include dizziness, drowsiness, confusion, numbness of the face or
extremities or the whole body, respiratory depression, twitching, dysarthria, diplopia, euphoria, tremors, and seizures (6063). Adverse cardiovascular effects of lidocaine include sinus
bradycardia, sinus arrest, atrioventricular conduction disturbances, asystole, hypotension, and respiratory arrest (62-66).
In trials evaluating the use of prophylactic lidocaine for the
prevention of primary VF or other arrhythmias in patients with
acute MI, the incidence of lidocaine-induced adverse effects has
ranged from 4% to 85% (15,16,18-22.45,47-49,53,54,56,58,67,
68). In some studies, no adverse effects attributable to lidocaine
therapy were reported (17,25,55,57), whereas other investigators failed to indicate whether any side effecls occurred (44,46).
The report of one large trial simply states that minor side effects
were "frequently observed" (26). In the study by Lie and associates (22), in which the incidence of primary VF was significantiy reduced by the prophylactic administration of lidocaine,
the incidence of adverse effects was 15% and was highest in patients greater than 60 years of age, prompting the authors to suggest that the benefits of prophylactic lidocaine administration
may not outweigh the risks in elderly patients. Dunn and colleagues (53) reported that the incidence of adverse effects within
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one hour following a loading dose of lidocaine (300 mg intramuscularly followed by 100 mg intravenously) was significantly higher than that in patients who received placebo. They
recommended against routine lidocaine prophylaxis in patients
with suspected acute MI.
Rademakerand associates (61) performed a systematic evaluation of the incidence and nature of lidocaine-induced adverse
effects during the course of a study investigating the efficacy of
prophylactic lidocaine administration following suspected or
confirmed acute Ml (49). A comparison of the incidence of minor, major, and life-threatening adverse effects in the lidocaine
and placebo groups is presented in Table 4. The overall incidence of adverse effects was significantly higher in patients who
received lidocaine than in those who received placebo (74
[51%] of 145 in the lidocaine group versus 22 [I6%] of 140 in
the placebo group). The incidences of each of the minor symptoms of dizziness, numbness, and slurred speech and the major
symptoms of confusion and slurred speech (listed as both a minor and major symptom) in the lidocaine group were significantiy higher compared to the placebo group. The incidences of
any minor symptom and any major symptom were also significantiy higher in the lidocaine group than in the placebo group.
The incidence of life-threatening problems in the two groups
was not significantiy different, although a trend towards a significantly higher incidence was demonstrated in the lidocaine
group. The probability of experiencing minor or major lidocaine-induced adverse effects was greatest within the first 12
hours of dmg administration. Of the patients who experienced
lidocaine-induced adverse effects, 88% did so within 24 hours
of the onset of therapy. The investigators also found that the incidence of minor lidocaine-induced adverse effects was significantiy greater in patients in whom acute MI was subsequentiy
ruled out than in those with confirmed MI. Major adverse effects
also occurred more frequently in patients without Ml than in
those with confirmed MI, but the difference did not reach statistical significance. Serum lidocaine concentrations were only
weakly related to lidocaine-induced adverse effects, and many
patients who experienced side effecls had serum lidocaine concentrations within the accepted therapeutic range (50). Based on
these data, the authors suggest that the risks of routine lidocaine
prophylaxis may outweigh any potential benefits.
In summary, based on the data provided by Rademaker and
colleagues (61), adverse effects direclly attributable to lidocaine
occur in approximately 35% of patients (16% in the placebo
group subtracted from 51% in the lidocaine group) with suspected or confirmed MI who receive the drug for the prevenfion
of primary VF. Lidocaine-induced adverse effects occur with
equal or greater incidence in pafients subsequently found not to
have had a MI compared to those with confirmed MI. Adverse
effects due to lidocaine are most likely to occur early in therapy
and may occur in patients with serum lidocaine concentrafions
within the accepted therapeutic range.

Summary and Recommendations
The administrafion of lidocaine for the prevenfion of primary
VF in patients with suspected Ml has been altematively advo-
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Table 4
Incidence of Adverse Effects in a Randomized, PlaceboControlled Trial of Prophylactic Lidocaine Administration
in Acute Myocardial Infarction*
Lidocaine
(n= 145)
Minor Symptoms:
Somnolence
Confusion
Dizziness
Numbness
Slurred speech
Any minor symptom
Major Adverse Effects:
Confusion
Slurred speech
Diplopia
Tremor
Severe nausea and vomiting
Sinus bradycardia (< 45 but > 35 bpm)
Any major adverse effect
Life-threatening Problems:
Sinus arrest/bradycardia (< 35 bpm)
Seizure
Coma/respiratory arrest
Any life-threatening problem

Placebo
(n= 140)

P-Value

14
7
43
13
14
67

8
1
10
0
5
20

0,21
0,07
< 0,0001
0,0002
0,04
< 0,0001

9
12
4
2

0
0
0
0
2
1
3

0,004
0,0005
0,13
0,50
0,06
0,99
< 0,0001

g
I
27
2
2
1
5

0
0
0
0

0,50
0,50
0,99
0,06

*From Rademaker AW, Kellen J, Tam YK, Wyse DG, Character of adverse effects of
prophylactic lidocaine in the coronary eare unit, Clin Pharmacol Ther 1986:40:71-80, Reprinted with permission.

cated (6,35,43,69,70) and discouraged (10,71) for over 20 years.
Based on data currently available in the literature, disadvantages
of routine lidocaine prophylaxis appear to outweigh potential
advantages. The incidence of primary VF following MI is only
2% to 10% and decreases as the duration of time from the onset
of symptoms to hospital admission increases. While the administration of prophylactic lidocaine has been shown to reduce the
incidence of primary VF following acute MI, a beneficial effect
on mortality has not been demonstrated, and evidence even suggests that prophylactic lidocaine administrafion may increase
mortality during the treatment period. Adverse effects occur in
approximately one-third of patients receiving prophylactic lidocaine and may occur with greater frequency in the substantial
group of patients with suspected Ml in whom the diagnosis of
acute MI is subsequently mied out. Based on data indicating that
the diagnosis of acute MI is confirmed in approximately 30% of
those in whom it is suspected (26), and assuming a risk of primary VF of 2% in those patients with MI, it has been estimated
that a policy of routine prophylactic lidocaine administration
would necessitate exposing approximately 150 patients to the
potential adverse effects of the drug in order to protect one from
VF (72) and none from mortality. Routine administration of
lidocaine to all patients with suspected acute MI is therefore not
recommended.
In lieu of administering lidocaine to all patients with suspected MI, administration of the drug only to those patients with
specific VEA ("warning arrhythmias") has been advocated.
However, specific VEA has been shown to be an in.sensitive and
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nonspecific predictor of the occurrence of primary VF following
acute MI. Nevertheless, the most recent guidelines of the American College of Cardiology and the American Heart Association
(73) recommend the administration of lidocaine for a period of
12 to 24 hours to patients with acute myocardial ischemia or MI
with VPBs that occur frequentiy (> 6/min), are closely coupled
(R on T), multiform in configuration, or occur in short bursts of
three or more in succession. These guidelines were formulated
prior to the publication of the meta-analysis which indicated that
lidocaine prophylaxis may adversely infiuence mortality (59).
Until the significance of these more recent data can be fully appreciated and updated recommendations become available, the
exisfing guidelines of the American College of Cardiology and
American Heart Association must be considered during treatment of patients with suspected acute MI.
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